Friday
Mar082013

SPARCtool Updated

version 6.21 release notes

SPARCmobile

  • updated the disclaimer
  • fixed truncated renal dysfunction warning for new OACs on iPhone and increased visibility of warnings.
  • changed text of the warnings to “RENAL FUNCTION WARNING: Consult product monograph.” - dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks

SPARCtool

  • updated the disclaimer
  • changed text of the warnings to "WARNING: may be contraindicated or require dosage reduction depending on degree of renal dysfunction. Consult your country's monograph."
  • dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks
  • added graphical representation of the risks (requires Adobe Flash to view)